JP2014510101A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510101A5 JP2014510101A5 JP2014500540A JP2014500540A JP2014510101A5 JP 2014510101 A5 JP2014510101 A5 JP 2014510101A5 JP 2014500540 A JP2014500540 A JP 2014500540A JP 2014500540 A JP2014500540 A JP 2014500540A JP 2014510101 A5 JP2014510101 A5 JP 2014510101A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- isolated peptide
- peptide
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 235000001014 amino acid Nutrition 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000000324 neuroprotective effect Effects 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466966P | 2011-03-24 | 2011-03-24 | |
| US61/466,966 | 2011-03-24 | ||
| PCT/IL2012/050104 WO2012127475A1 (en) | 2011-03-24 | 2012-03-22 | Neuroprotective peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510101A JP2014510101A (ja) | 2014-04-24 |
| JP2014510101A5 true JP2014510101A5 (enExample) | 2015-05-14 |
| JP5960793B2 JP5960793B2 (ja) | 2016-08-02 |
Family
ID=45999925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014500540A Active JP5960793B2 (ja) | 2011-03-24 | 2012-03-22 | 神経保護ペプチド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140045764A1 (enExample) |
| EP (1) | EP2688582B1 (enExample) |
| JP (1) | JP5960793B2 (enExample) |
| KR (1) | KR20140036164A (enExample) |
| CN (1) | CN103648517B (enExample) |
| AU (1) | AU2012232642B2 (enExample) |
| BR (1) | BR112013024323A2 (enExample) |
| CA (1) | CA2830792A1 (enExample) |
| EA (1) | EA201391387A1 (enExample) |
| MX (1) | MX2013010910A (enExample) |
| SG (1) | SG193418A1 (enExample) |
| WO (1) | WO2012127475A1 (enExample) |
| ZA (1) | ZA201307169B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201220899D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived pegylated peptides |
| EP3409130B1 (en) * | 2016-01-27 | 2020-11-25 | Industry-Academic Cooperation Foundation Gyeongsang National University | Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors |
| WO2017170924A1 (ja) * | 2016-03-31 | 2017-10-05 | 千寿製薬株式会社 | 神経保護ペプチド |
| US10660934B2 (en) | 2016-03-31 | 2020-05-26 | Senju Pharmaceutical Co., Ltd. | Neuroprotective peptide |
| EP3712164A4 (en) | 2017-11-14 | 2021-08-18 | Senju Pharmaceutical Co., Ltd. | PEPTIDE STABILIZED BY PACAP |
| EP3876870B1 (en) | 2018-11-08 | 2023-12-20 | Neovasc Tiara Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
| JPWO2020230869A1 (enExample) | 2019-05-14 | 2020-11-19 | ||
| JPWO2020230867A1 (enExample) | 2019-05-14 | 2020-11-19 | ||
| CN112569351B (zh) * | 2020-12-16 | 2021-10-15 | 南通大学 | Cd44抗体在制备治疗帕金森疾病的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| DK0703989T3 (da) * | 1993-06-18 | 1998-02-09 | Biotie Therapies Oy | Præparater og diagnostiske fremgangsmåder under anvendelse af monoklonale antistoffer mod CD44v6 |
| CA2179391A1 (en) * | 1994-01-18 | 1995-07-20 | Edgar Haber | Cd44 expression in smooth muscle cells |
| DE19653607A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Int | Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen |
| US6559287B1 (en) * | 1998-01-24 | 2003-05-06 | Bristol-Myers Squibb Co. | Artificial proteoglycans |
| ES2343797T3 (es) * | 2004-10-14 | 2010-08-10 | Karlsruher Institut Fur Technologie | Compuestos peptidicos y sus derivados para el tratamiento de enfermedades humanas mediante la inhibicion de la via de señalizacion por factores de crecimiento. |
| NZ582390A (en) * | 2007-07-10 | 2012-05-25 | Neurim Pharma 1991 | Cd44 splice variants in neurodegenerative diseases |
| EP2266593A1 (en) * | 2009-06-24 | 2010-12-29 | Karlsruher Institut für Technologie | Use of CD44v6 in the treatment of ophthalmic diseases |
-
2012
- 2012-03-22 EP EP12716661.9A patent/EP2688582B1/en active Active
- 2012-03-22 BR BR112013024323A patent/BR112013024323A2/pt not_active Application Discontinuation
- 2012-03-22 KR KR1020137027914A patent/KR20140036164A/ko not_active Withdrawn
- 2012-03-22 SG SG2013068499A patent/SG193418A1/en unknown
- 2012-03-22 EA EA201391387A patent/EA201391387A1/ru unknown
- 2012-03-22 MX MX2013010910A patent/MX2013010910A/es not_active Application Discontinuation
- 2012-03-22 US US14/007,010 patent/US20140045764A1/en not_active Abandoned
- 2012-03-22 CA CA2830792A patent/CA2830792A1/en not_active Abandoned
- 2012-03-22 CN CN201280014793.1A patent/CN103648517B/zh active Active
- 2012-03-22 JP JP2014500540A patent/JP5960793B2/ja active Active
- 2012-03-22 WO PCT/IL2012/050104 patent/WO2012127475A1/en not_active Ceased
- 2012-03-22 AU AU2012232642A patent/AU2012232642B2/en active Active
-
2013
- 2013-09-18 ZA ZA2013/07169A patent/ZA201307169B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510101A5 (enExample) | ||
| JP2019513752A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| NZ611620A (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
| JP2014501510A5 (enExample) | ||
| EA202090053A2 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| WO2012142320A3 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| JP2012082206A5 (enExample) | ||
| JP2010534684A5 (enExample) | ||
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| JP2011521902A5 (enExample) | ||
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| JP2014514365A5 (enExample) | ||
| JP2013523718A5 (enExample) | ||
| JP2015523072A5 (enExample) | ||
| WO2014202622A3 (en) | Rasamsonia gene and use thereof | |
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| JP2014510735A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| JP2015521206A5 (enExample) | ||
| JP2019535267A5 (enExample) | ||
| JP2012102105A5 (enExample) | ||
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| JP2011528334A5 (enExample) | ||
| JP2010265269A5 (enExample) |